Equity intelligence report • June 26, 2026
Bio-Rad Laboratories is navigating significant financial challenges despite reporting a quarterly earnings surpassing expectations. The latest results show earnings per share (EPS) of $3.38, yet the company faces a revenue decline to $691.1 million, a 7.2% decrease from the previous year. This decline is compounded by a previous GAAP net loss of $527.1 million in Q1 2026 and ongoing stock volatility after recent mergers and acquisitions, including the contentious acquisition of Stilla Technologies. While the Life Science segment continues to grow, Bio-Rad has cut its revenue guidance, projecting modest growth for the upcoming year amidst persistent market pressures and investor scrutiny.
Click a month on the chart to update the report below.
